Given the circumstances of the COVID-19 pandemic, many U.S.-based pharmaceutical manufacturers are suddenly faced with a hard truth: They have a supply chain problem. Specifically, they’re realizing that their existing overseas gelatin capsule supplier may not be able to continue to provide reliable production and delivery.